Re-engineering islet cell transplantation

Nicoletta Fotino; Carmen Fotino; Antonello Pileggi

doi:10.1016/j.phrs.2015.02.010

Re-engineering islet cell transplantation

Pharmacol Res. 2015 Aug:98:76-85. doi: 10.1016/j.phrs.2015.02.010. Epub 2015 Mar 23.

Authors

Nicoletta Fotino¹, Carmen Fotino², Antonello Pileggi³

Affiliations

¹ Cell Transplant Center, Diabetes Research Institute, University of Miami, USA; University of Pisa, Italy.
² Cell Transplant Center, Diabetes Research Institute, University of Miami, USA.
³ Cell Transplant Center, Diabetes Research Institute, University of Miami, USA; Departments of Surgery, Miller School of Medicine, University of Miami, USA; Departments of Microbiology and Immunology, Miller School of Medicine, University of Miami, USA; Department of Biomedical Engineering, University of Miami, USA. Electronic address: [email protected].

Abstract

We are living exciting times in the field of beta cell replacement therapies for the treatment of diabetes. While steady progress has been recorded thus far in clinical islet transplantation, novel approaches are needed to make cell-based therapies more reproducible and leading to long-lasting success. The multiple facets of diabetes impose the need for a transdisciplinary approach to attain this goal, by targeting immunity, promoting engraftment and sustained functional potency. We discuss herein the emerging technologies applied to this rapidly evolving field.

Keywords: Beta cells; Biomaterials; Cellular therapies; Diabetes; Implantable devices; Insulin; Islet transplantation; Islets of Langerhans; Stem cells; Tissue engineering.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Bioengineering
Diabetes Mellitus / metabolism
Diabetes Mellitus / surgery*
Diabetes Mellitus, Type 1 / surgery
Humans
Immunomodulation
Islets of Langerhans Transplantation / methods*

Abstract

Publication types

MeSH terms

Grants and funding